Latest news with #XOMARoyaltyCorporation
Washington Post
13-05-2025
- Business
- Washington Post
XOMA Royalty: Q1 Earnings Snapshot
EMERYVILLE, Calif. — EMERYVILLE, Calif. — XOMA Royalty Corporation (XOMA) on Tuesday reported first-quarter earnings of $2.4 million. On a per-share basis, the Emeryville, California-based company said it had profit of 6 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share.
Yahoo
07-05-2025
- Business
- Yahoo
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
XOMA Royalty Corporation EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025. Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET. Mr. Hughes will join the 'Pros and Cons of Royalty Model – Especially in Current Financing Environment' panel discussion at 4:00 PM ET. Mr. Sitko will participate in the 'Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?' panel at 5:00 PM ET. Registration for the conference can be accessed by visiting XOMA Royalty's presentations can be accessed by visiting the investor relations section of the Company's website at In addition, members of XOMA Royalty's business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held on May 20, 2025, in New York, NY. About XOMA Royalty Corporation XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit or follow XOMA Royalty Corporation on LinkedIn. XOMA Investor Contact Juliane Snowden XOMA Royalty +1 646-438-9754 XOMA Media Contact Kathy Vincent KV Consulting & Management kathy@
Yahoo
09-04-2025
- Business
- Yahoo
XOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump's Tariff Rollout
We recently published a list of . In this article, we are going to take a look at where XOMA Royalty Corporation (NASDAQ:XOMA) stands against other stocks that insiders bought in April after Trump's tariff rollout. President Donald Trump called April 2 a 'Liberation Day' after signing an executive order that imposed a minimum 10% tariff on all U.S. imports, with some exceptions. As a result, 57 countries will face higher tariffs ranging from 11% to 50%. While general tariffs took effect on April 5, the elevated rates are set to begin on April 9. These so-called 'reciprocal tariffs' triggered retaliation from trade partners and contributed to a decline in the stock market.' On Sunday, Trump said, 'I don't want anything to go down, but sometimes you have to take medicine to fix something,' as reported by CNBC. The blue-chip companies closed the Monday market session 0.91% lower, while the broader market index closed 0.23% lower after briefly entering bear market territory during the session. The Nasdaq Composite closed 0.10% higher. Amid these tariff wars and overwhelming market uncertainty, insider trading often comes to focus. Why? When executives buy stock, it can suggest confidence in the company's future. On the other hand, insider sales don't have to be a negative sign for the company, because they can reflect personal decisions or investment diversification. This means that insider trading should be considered alongside the company's financial health and market conditions. Today, we're focusing on stocks that insiders have been buying in April. Using Insider Monkey's insider trading screener, we identified companies where at least one insider acquired shares from April 2 to April 7. From this list, we ranked the top 20 stocks with the highest value of insider purchases. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A medical professional holding vials of biotechnology therapeutic candidate. XOMA Royalty is a biotech royalty aggregator focused on early to mid-stage clinical assets and late-stage commercial ones. It holds economic rights to milestone and royalty payments from partnered therapeutic candidates. The company, headquartered in Emeryville, California, was formerly known as XOMA Corporation and changed its name in July 2024. This month, one insider acquired approximately $760,145 worth of XOMA Royalty shares at an average price of $25.41 per share. Year-to-date, the stock is down 26.05%, trading at $19.43 per share. Over the past 12 months, the stock lost 23.00%. XOMA Royalty reported total income and revenues of $8.7 million and $28.5 million for the fourth quarter and full year of 2024, respectively. In 2023, XOMA Royalty recorded total income and revenues of $1.8 million and $4.8 million for the fourth quarter and full year, respectively. The increase for the full year of 2024 was primarily driven by an increase in the company's income from purchased receivables. Based on three Wall Street analysts' estimates, XOMA Royalty stock is a 'Moderate Buy' with a price target of $79.50 per share, according to TipRanks. The average price target suggests a 299.50% upside from the latest price. Overall, XOMA ranks 18th on our list of stocks that insiders bought in April after Trump's tariff rollout. While we acknowledge the potential of XOMA, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XOMA but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
24-02-2025
- Business
- Yahoo
XOMA Royalty to Present at Investor Conferences in March
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings. T.D. Cowen 45th Annual Health Care Conference (March 3-5, 2025) Format:Date:Time: Corporate presentationMonday, March 3, 202511:10AM ET Location:Link: Boston, MAhttps:// Leerink 2025 Global Healthcare Conference (March 9-12, 2025) Format: Fireside chat Date: Monday, March 10, 2025 Time: 2:20PM ET Location:Link: Miami Beach, FLhttps:// XOMA's presentations can also be accessed by visiting the investor relations section of the Company's website at A replay of each presentation will be available and archived on the site for 90 days after the event. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit or follow XOMA Royalty Corporation on LinkedIn. XOMA Investor Contact XOMA Media Contact Juliane Snowden Kathy Vincent XOMA Royalty KV Consulting & Management +1 646-438-9754 +1 310-403-8951 kathy@ in to access your portfolio
